| JKB-122 | |
| JKB-122 is an investigational small molecule, long-acting toll-like receptor 4 (TLR4) antagonist developed for autoimmune hepatitis and nonalcoholic fatty liver disease. The drug was transferred to Biostax in 2022. | |
| References |
| JKB-122 | |
| JKB-122 is an investigational small molecule, long-acting toll-like receptor 4 (TLR4) antagonist developed for autoimmune hepatitis and nonalcoholic fatty liver disease. The drug was transferred to Biostax in 2022. | |
| References |